Ligand id: 10208

Name: ibalizumab

Compound class Antibody
Approved drug? Yes (FDA (2018), EMA (2019))
International Nonproprietary Names
INN number INN
8818 ibalizumab
Hu5A8 | ibalizumab-uiyk | TMB-355 | TMB355 | TNX-355 | Trogarzo®
Ibalizumab was originally reported as anti-CD4 monoclonal antibody 5A8 by Burkly et al. (1992 ) [1]. It is a non-immunosuppressive, humanised monoclonal antibody that acts as an HIV entry inhibitor [2,4]. Anti-HIV activity of TNX-355 (later to be assigned the INN ibalizumab) in patients was reported in 2004 [5].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Database Links
Specialist databases
IMGT/mAb-DB 241
Other databases
GtoPdb PubChem SID 381744890
Search PubMed clinical trials ibalizumab
Search PubMed titles ibalizumab
Search PubMed titles/abstracts ibalizumab